SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
216 hedge funds and large institutions have $2.92B invested in SpringWorks Therapeutics in 2024 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 89 increasing their positions, 63 reducing their positions, and 44 closing their positions.
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
41% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 63
13% more capital invested
Capital invested by funds: $2.59B → $2.92B (+$334M)
0.01% less ownership
Funds ownership: 108.77% → 108.76% (-0.01%)
4% less funds holding
Funds holding: 226 → 216 (-10)
16% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 44
17% less call options, than puts
Call options by funds: $10.4M | Put options by funds: $12.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$54.5M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$39.7M |
| 3 |
Morgan Stanley
New York
|
+$19.5M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
+$16.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$62.9M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$23.8M |
| 3 |
PA
Perceptive Advisors
New York
|
-$22.2M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$15.5M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$13.4M |
SWTX Hedge Fund Activity: Q4 2024 in Review
216 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q4 2024, worth a combined $2.92B — up 13% from $2.59B a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of SWTX and 37 opened new positions — a net loss of 7 holders — while 63 trimmed existing stakes and 89 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $54.5M. The largest seller was Marshall Wace, exiting entirely with an estimated $62.9M sold.
- 216 institutional investors held SpringWorks Therapeutics (SWTX) as of Q4 2024, down from 226 in Q3 2024.
- Funds reported $2.92B of SpringWorks Therapeutics stock for Q4 2024, up 13% quarter-over-quarter.
- 37 funds opened new SpringWorks Therapeutics positions in Q4 2024 and 44 closed out, a net change of -7 holders.
- The largest SpringWorks Therapeutics buyer in Q4 2024 was EcoR1 Capital, an estimated $54.5M added.
- The largest SpringWorks Therapeutics seller in Q4 2024 was Marshall Wace, an estimated $62.9M sold.
Based on aggregated 13F filings for Q4 2024.